UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 24, 2008
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TRANSACTION IN OWN SHARES
NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME
On 15 August 2008 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount of up to
DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008.
Since the announcement as of 17 November 2008, the following transactions have
been made under the programme:
NUMBER OF AVERAGE TRANSACTION
SHARES PURCHASE PRICE VALUE, DKK
ACCUMULATED, LAST
ANNOUNCEMENT 3,626,500 1,032,250,004
17 November 2008 50,000 295.7000 14,785,000
18 November 2008 50,000 287.9700 14,398,500
19 November 2008 50,000 284.8000 14,240,000
20 November 2008 75,000 287.2300 21,542,250
21 November 2008 100,000 275.1500 27,515,000
ACCUMULATED UNDER
THE PROGRAMME 3,951,500 1,124,730,754
With the transactions stated above, Novo Nordisk owns a total of 24,918,285
treasury shares, corresponding to 3.9% of the share capital. The total amount of
shares in the company is 634,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in
80 countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Outside North America Mads Veggerby Lausten
Elin K Hansen Tel: (+45) 4443 7919
Tel: (+45) 4442 3450 mlau@novonordisk.com
ekh@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America:
Sean Clements Kasper Roseeuw Poulsen
Tel: (+1) 609 514 8316 Tel: (+45) 4442 4471
secl@novonordisk.com krop@novonordisk.com
Company Announcement no 77 / 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: November 24, 2008 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer